Download PDF PALO ALTO, Calif., Nov. 8, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will report third quarter 2019 results on Tuesday, November 12, 2019.  Following the release of results, Kodiak will host a business highlights webcast at 2:00 p.m. Pacific … Continued

Promising clinical durability observed with 80% of wet AMD treated eyes and 78% of DME treated eyes extended to four months or longer without receiving retreatment Strong anti-VEGF efficacy continues to be observed across the major retinal vascular diseases Encouraging safety profile with zero cases of intraocular inflammation after 300+ doses in 100+ patients PALO … Continued

PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD) will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic candidate KSI-301. The R&D event, including a live video stream, will be held on Monday, October 14 from 8:00 – 10:30a.m. Pacific Time in San Francisco, CA. At the R&D Day, Kodiak senior management, … Continued

PALO ALTO, Calif., Oct. 10, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that the first patients have been treated in the DAZZLE pivotal study of Kodiak’s anti-VEGF antibody biopolymer conjugate, KSI-301, in patients with treatment-naïve wet (neovascular) age-related macular degeneration (AMD). “Treating … Continued

PALO ALTO, Calif., Oct. 7, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that Charles C. Wykoff, M.D., Ph.D., will present first-time results at the Annual Meeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco, California. The Retina Subspecialty Day (October … Continued

Late-breaking results support Kodiak’s objective of every three-, four-, and five-month long-interval dosing of KSI-301 in patients with wet AMD KSI-301 continues towards its development goals of demonstrating safety and efficacy (with over 250 injections given to over 100 patients with no intraocular inflammation) and now promising durability data PALO ALTO, Calif., Sept. 15, 2019 /PRNewswire/ — Kodiak … Continued

Late-Breaking Results Include First Durability Data from Phase 1b Study of KSI-301 in Treatment-Naïve Patients with Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion PALO ALTO, Calif., Sept. 12, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that … Continued

PALO ALTO, Calif., Sept. 6, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will participate in the Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9 at 4:50 p.m. Eastern Time. A live … Continued

PALO ALTO, Calif., Sept. 4, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that presentations on its research will be made at EURETINA 2019 Congress being held from September 5 – 8 in Paris, France. “We continue to be … Continued

PALO ALTO, Calif., Aug. 14, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the second quarter ended June 30, 2019. “During the second quarter, we expanded enrollment in our Phase 1b study … Continued